Complement System

Overview

The complement system is a proteolytic cascade of serum proteins and membrane-associated regulators that constitutes a major effector arm of innate immunity. Discovered in the 1890s as a heat-labile serum factor that complemented antibody-mediated bacterial killing, the system comprises over 30 proteins that circulate in inactive forms and are sequentially activated upon pathogen detection or immune complex formation.

Complement activation proceeds through three initiation pathways — classical, lectin, and alternative — all of which converge on a common terminal pathway that generates three principal outcomes: opsonization (tagging pathogens for phagocytosis), inflammation (releasing anaphylatoxin peptides C3a and C5a), and direct pathogen lysis (assembling the membrane attack complex, MAC). In peptide research, the complement system is relevant both because its activation generates bioactive peptide fragments (C3a, C5a, C4a) and because certain research peptides modulate complement-mediated inflammatory responses.

How It Works

Classical Pathway

The classical pathway is initiated by antigen-antibody complexes and provides a bridge between adaptive and innate immunity.

1. C1q, a hexameric recognition protein resembling a bouquet of tulips, binds to the Fc regions of IgG or IgM antibodies complexed with antigen. At least two Fc regions must be engaged for stable C1q binding, which is why pentameric IgM is the most efficient classical pathway activator.
2. C1q binding activates C1r, a serine protease, which cleaves and activates C1s (another serine protease). Together, C1q, C1r, and C1s form the C1 complex.
3. Active C1s cleaves C4 into C4a (small fragment, released) and C4b (large fragment, which covalently binds the target surface via a reactive thioester bond).
4. Surface-bound C4b binds C2, which is cleaved by C1s into C2a (the catalytic fragment that remains bound to C4b) and C2b (released).
5. The C4b2a complex is the classical pathway C3 convertase — the central amplification enzyme of the cascade.

Lectin Pathway

The lectin pathway is activated by microbial carbohydrate patterns independently of antibodies.

1. Mannose-binding lectin (MBL) or ficolins (ficolin-1, -2, -3) recognize pathogen-associated carbohydrate patterns (mannose, N-acetylglucosamine, fucose) on microbial surfaces.
2. MBL-associated serine proteases (MASP-1, MASP-2, MASP-3) are activated upon pattern recognition.
3. MASP-2 cleaves C4 and C2 identically to C1s in the classical pathway.
4. The lectin pathway generates the same C3 convertase (C4b2a) as the classical pathway.

Alternative Pathway

The alternative pathway provides constitutive, low-level complement surveillance through spontaneous C3 activation.

1. C3 undergoes spontaneous hydrolysis (tick-over) at a low rate, generating C3(H2O), which exposes a reactive thioester and binds Factor B.
2. Factor D (a constitutively active serine protease) cleaves Factor B bound to C3(H2O), generating Bb (catalytic fragment) and Ba (released).
3. C3(H2O)Bb is the initial alternative pathway C3 convertase — it cleaves C3 into C3a (anaphylatoxin, released) and C3b (opsonin, deposited on surfaces).
4. Surface-deposited C3b binds Factor B, which is cleaved by Factor D to form C3bBb — the amplification C3 convertase of the alternative pathway.
5. Properdin (Factor P) stabilizes C3bBb on activating surfaces, extending its half-life from 90 seconds to approximately 30 minutes.

Amplification loop — Regardless of which pathway initiates the cascade, C3b generated by any C3 convertase feeds into the alternative pathway amplification loop. This amplification loop generates approximately 80% of total complement activation products, even when the classical or lectin pathway is the initial trigger.

Terminal Pathway and Membrane Attack Complex

All three pathways converge at C3 convertase formation, which leads to the terminal pathway:

1. C3 convertases (C4b2a or C3bBb) deposit large amounts of C3b on the target surface.
2. C3b binds to the C3 convertase itself, forming C5 convertases (C4b2a3b or C3bBb3b).
3. C5 convertases cleave C5 into C5a (potent anaphylatoxin, released) and C5b (initiates MAC assembly).
4. C5b sequentially recruits C6, C7, C8, and multiple copies of C9.
5. C9 polymerizes to form a transmembrane pore — the membrane attack complex (MAC) — approximately 10 nm in diameter.
6. MAC insertion disrupts membrane integrity, causing osmotic lysis of the target cell.

Anaphylatoxins: Complement-Derived Peptides

The small fragments C3a, C4a, and C5a released during complement activation are bioactive peptides with significant inflammatory effects:

C5a — The most potent anaphylatoxin. Acts through the GPCR C5aR1 (CD88) to cause neutrophil chemotaxis, oxidative burst activation, mast cell degranulation, vascular permeability increase, and smooth muscle contraction. C5a is also a chemoattractant for monocytes and macrophages.

C3a — Acts through C3aR (a GPCR) to cause mast cell degranulation, smooth muscle contraction, and eosinophil activation. C3a also has antimicrobial peptide activity against Gram-negative bacteria.

C4a — The weakest anaphylatoxin. Its receptor has been identified as the protease-activated receptor PAR1/PAR4 in some contexts, though its physiological significance remains debated.

Regulation

Complement is tightly regulated to prevent damage to self tissues:

• C1 inhibitor (C1-INH) — Serine protease inhibitor; inactivates C1r, C1s, MASP-1, MASP-2
• Factor H — Binds C3b on self surfaces (recognizing host sialic acid), accelerates C3bBb decay, and serves as cofactor for Factor I-mediated C3b cleavage
• Factor I — Serine protease; cleaves C3b to iC3b (assisted by cofactors: Factor H, MCP, CR1)
• CD59 (protectin) — Membrane protein that prevents C9 polymerization, blocking MAC formation on self cells
• DAF (CD55) — Accelerates decay of both classical and alternative C3/C5 convertases on self surfaces
• MCP (CD46) — Membrane cofactor for Factor I-mediated C3b/C4b cleavage

Key Components

Role in Peptide Research

Anaphylatoxins as Bioactive Peptides

C3a and C5a are themselves peptides (77 and 74 amino acids, respectively) generated by complement activation. They signal through GPCRs (C3aR, C5aR1) and represent endogenous peptide mediators of inflammation. Synthetic C5a receptor antagonists and C3a analogs are investigated as anti-inflammatory therapeutics, demonstrating the intersection of complement biology and peptide pharmacology.

BPC-157 and Complement-Mediated Inflammation

BPC-157 has documented anti-inflammatory effects in models of tissue injury where complement activation contributes to pathology, including ischemia-reperfusion injury and colitis. While direct effects of BPC-157 on complement components have not been extensively characterized, its cytoprotective effects in complement-activating conditions suggest potential modulation of downstream complement-mediated inflammatory responses.

Thymosin Alpha-1 and Immune Modulation

Thymosin alpha-1 modulates innate immune responses that include complement-dependent processes. By enhancing dendritic cell function and TLR signaling, thymosin alpha-1 may influence the coordination between complement activation and adaptive immune priming that is essential for effective pathogen clearance.

LL-37 and Complement Cross-Talk

The antimicrobial peptide LL-37 (cathelicidin) interacts with complement components and can modulate complement activation on bacterial surfaces. This cross-talk between antimicrobial peptides and complement represents a broader theme in innate immunity where peptide effectors and the complement cascade operate synergistically.

Clinical Significance

• Paroxysmal nocturnal hemoglobinuria (PNH) — Loss of GPI-anchored complement regulators (CD55, CD59) on blood cells causes complement-mediated hemolysis. Eculizumab, a monoclonal antibody blocking C5 cleavage, was the first complement-targeted therapy and transformed PNH treatment.
• Atypical hemolytic uremic syndrome (aHUS) — Uncontrolled alternative pathway activation due to Factor H, Factor I, or MCP mutations causes thrombotic microangiopathy. Eculizumab and ravulizumab are standard treatments.
• Hereditary angioedema — C1-INH deficiency causes episodic swelling mediated by bradykinin (generated when uncontrolled C1s activates the contact system). Recombinant C1-INH and kallikrein inhibitors are used therapeutically.
• Age-related macular degeneration — Complement Factor H polymorphisms (Y402H) are the strongest genetic risk factor for AMD. Complement-targeted therapies (pegcetacoplan, a C3 inhibitor) are approved for geographic atrophy.
• COVID-19 — Complement activation contributes to the thromboinflammation seen in severe COVID-19. C5a and C3a levels correlate with disease severity, and complement inhibition was investigated as a therapeutic strategy.
• Transplant rejection — Antibody-mediated rejection activates the classical complement pathway, causing graft injury. Complement inhibitors are investigated as adjunctive immunosuppressants.

Related Topics

• Toll-Like Receptors — Cooperate with complement in innate pathogen recognition
• NF-kB Pathway — Anaphylatoxin signaling activates NF-kB in immune cells
• Apoptosis Pathways — Sublytic MAC activates cell survival signaling; lytic MAC causes necrosis
• Nitric Oxide System — NO modulates complement-mediated vascular inflammation
• GPCR Signaling — C3aR and C5aR1 are GPCRs transducing anaphylatoxin signals